Recro eyes expansion to full-service CDMO status
The solid oral dose specialist signs letter of intent for acquisition of a CDMO providing a full range of services
Recro Pharma, a CDMO specialising in providing complex formulation and manufacturing services for companies developing oral solid dose drug products, is looking to spread its wings by signing a non-binding letter of intent for the acquisition of a full service CDMO.
In a statement, Recro said the unnamed company in question has capabilities ranging from formulation development to commercial manufacturing for various dosage forms including oral liquids, sterile injectables, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles.
Should the acquisition complete, Recro will acquire 100% of the company for approximately $50 million.
Recro's President and Chief Executive Officer David Enloe said: “We are excited about this potential transaction and look forward to closing and sharing more details in the near term."
Currently, the CDMO has two sites in Gainesville, GA, with development and manufacturing space covering 120,000 sq. ft.
Earlier this week, the company reported strong financial results for Q2, during which time it secured new projects with Astex Pharmaceuticals and Ensysce Biosciences, as well as a new unnamed customer.
In a statement reporting these results, Enloe said the company had "continued to expand and diversify" its customer base, and "significantly" strengthened its financial position.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.